This study is in progress, not accepting new patients
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Nektar Therapeutics
- ID
- NCT04410445
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- At least 775 people participating
- Last Updated